Eli Lilly to Buy DICE Therapeutics in $2.4 Billion Autoimmune Disease Push
Lilly says its acquisition of Dice for $48 a share would allow it to leverage the company's developing treatments for chronic diseases in immunology.
Stay updated with breaking news from Daniel Acker Bloomberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lilly says its acquisition of Dice for $48 a share would allow it to leverage the company's developing treatments for chronic diseases in immunology.
The Uncrustables brand is boosting sales for J.M. Smucker, which is in part because of broad appeal, according to CFO Tucker Marshall
A gay bar decided to take Anheuser-Busch products off their shelves after the owner claims that the company is inconsistent with its support of Dylan Mulvaney
CBC's Marketplace rounds up the consumer and health news you need from the week.
New study finds therapy doesn’t raise heart attack, stroke risks when administered properly